Recommendations for clinical trial development in follicular lymphoma
K Maddocks, PM Barr, BD Cheson… - Journal of the …, 2017 - academic.oup.com
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
Recommendations for Clinical Trial Development in Follicular Lymphoma.
K Maddocks, PM Barr, BD Cheson, RF Little… - Journal of the …, 2016 - europepmc.org
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
Recommendations for Clinical Trial Development in Follicular Lymphoma
K Maddocks, PM Barr, BD Cheson… - Journal of the …, 2016 - pubmed.ncbi.nlm.nih.gov
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
Recommendations for clinical trial development in follicular lymphoma
K Maddocks, PM Barr, BD Cheson… - Journal of the …, 2017 - scholars.northwestern.edu
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
Recommendations for clinical trial development in follicular lymphoma
K Maddocks, PM Barr… - Journal of the …, 2017 - mdanderson.elsevierpure.com
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
Recommendations for clinical trial development in follicular lymphoma
K Maddocks, PM Barr, BD Cheson… - Journal of the …, 2017 - profiles.wustl.edu
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
[HTML][HTML] Recommendations for Clinical Trial Development in Follicular Lymphoma
K Maddocks, PM Barr, BD Cheson… - JNCI Journal of the …, 2017 - ncbi.nlm.nih.gov
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
[PDF][PDF] Recommendations for Clinical Trial Development in Follicular Lymphoma
K Maddocks, PM Barr, BD Cheson, RF Little, L Baizer… - cancer.gov
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
Recommendations for clinical trial development in follicular lymphoma
K Maddocks, PM Barr, BD Cheson… - Journal of the …, 2017 - ohiostate.elsevierpure.com
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
Recommendations for Clinical Trial Development in Follicular Lymphoma
K Maddocks, PM Barr, BD Cheson, RF Little… - JNCI: Journal of the …, 2017 - iro.uiowa.edu
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …